USPTO Patent Grants - Organic Chemistry (C07D)

Salt Inducible Kinase Inhibitors Patent Granted to General Hospital Corporation

USPTO granted patent US12600719B2 to General Hospital Corporation covering salt inducible kinase (SIK) inhibitor compounds and pharmaceutical compositions. Inventors Marc Nathan Wein and William J. Greenlee filed the application on August 5, 2021. The patent contains 20 claims under CPC classification C07D 471/04.

Tricyclic KRAS Inhibitor Patent - Incyte Corporation

The USPTO granted Patent US12600717B2 to Incyte Corporation on April 14, 2026 for tricyclic compounds as inhibitors of KRAS activity. The patent contains 34 claims covering Formula I compounds useful in treating diseases associated with KRAS activity, including cancer. Filing date was July 13, 2022, under application number 17812310.

Washington University Patent for Toxoplasma Gondii Treatment Compounds

The USPTO granted Patent US12600727B2 to Washington University on April 14, 2026, covering compounds and methods for treating infections caused by Toxoplasma gondii and related parasites. The patent includes 18 claims and lists inventors L. David Sibley, Joshua Radke, Eamon Comer, Marshall Morningstar, and Bruno Melillo. This grant provides Washington University with exclusive intellectual property rights for the developed antiparasitic compounds and their pharmaceutical applications.

ELI LILLY AND COMPANY - KRAS Inhibitor Compounds for Cancer Treatment Patent Grant

The USPTO granted Patent US12600733B2 to Eli Lilly and Company on April 14, 2026, covering KRAS inhibitor compounds for treating cancer. The patent includes 30 claims for compounds of specified formula and their use in pharmaceutical compositions. Filing date was September 30, 2025.

NURIX BTK Degrading Compounds, 36 Claims, Apr 14

The USPTO granted Patent US12600732B2 to NURIX THERAPEUTICS, INC. on April 14, 2026. The patent covers 36 claims for bifunctional compounds that degrade BTK via the ubiquitin proteolytic pathway, along with pharmaceutical compositions and methods of treatment for various diseases, conditions, or disorders.

ONO Pharmaceutical ABHD6 Antagonist Patent US12600730B2

USPTO granted Patent US12600730B2 to ONO Pharmaceutical Co., Ltd. on April 14, 2026, covering substituted cyclopenta[c]pyrrole compounds as ABHD6 antagonists for pharmaceutical use. The patent includes 18 claims for compounds useful in preventing or treating diseases associated with ABHD6 enzyme inhibition. The application was filed on April 8, 2024.

Interleukin-17 Inhibitors Patent - Novartis AG

The USPTO granted patent US12600728B2 to NOVARTIS AG covering novel pyridine-N oxide substituted 2-formamido (N-phenyl and N-pyridyl) acetamide compounds as Interleukin-17 (IL-17) inhibitors. The patent also protects processes for preparing these compounds, pharmaceutical compositions, and medicaments for treating diseases and disorders mediated by IL-17.

Vanderbilt Cyclopropylpiperidine M4 Antagonists - US12600726B2

The USPTO granted Patent No. US12600726B2 to Vanderbilt University on April 14, 2026, covering cyclopropylpiperidine compounds useful as antagonists of muscarinic acetylcholine receptor M4 (mAChR M4). The patent includes 15 claims and covers methods of making the compounds, pharmaceutical compositions, and methods of treating disorders using the compounds. Vanderbilt University receives enforceable IP rights for this therapeutic compound class.

Nanjing University of Chinese Medicine - US12600724B2 Indole Alkaloid Compound and Preparation Method

The USPTO granted Patent US12600724B2 to Nanjing University of Chinese Medicine for an indole alkaloid compound represented by formula (I), including its preparation method and pharmaceutical salts. The compound has demonstrated therapeutic effects in animal studies, including promoting axon growth in peripheral sensory neurons, improving nerve conduction velocity in diabetic rats, accelerating foot ulcer wound healing, reducing pulmonary fibrosis, and protecting lung tissues. The patent contains 13 claims covering the compound, formulations, and methods of treatment for diabetic complications.

Tetracyclic DGK Inhibitor Compounds for Cancer Treatment

USPTO granted Patent US12600722B2 to Incyte Corporation for tetracyclic compounds that modulate diacylglycerol kinase (DGK) activity, useful in treating cancer including solid tumors. The patent names Joshua Hummel, Shicheng Shi, and Xiaozhao Wang as inventors and contains 63 claims.

Evotec Heterocyclic Drug Patent, Apr 14

Evotec Heterocyclic Drug Patent, Apr 14

Low-Viscosity Hardener Manufacturing Method Patent

USPTO granted patent US12600706B2 to Nan Ya Plastics Corporation for a method of manufacturing low-viscosity hardener using isomerization of 3-methyltetrahydrophthalic anhydride and 4-methyltetrahydrophthalic anhydride. The patent covers a hardener crude product with a weight ratio of 3:7 to 7:3 between the two anhydrides, producing a final viscosity of 30-50 cps. The patent includes 8 claims and names Te-Chao Liao, Jung-Jen Chuang, Chung-Yu Chen, and Jung-Tsu Wu as inventors.

Gannex Pharma FXR Modulating Compound Patent US12600716B2

USPTO granted patent US12600716B2 to Gannex Pharma Co. Ltd. on April 14, 2026, for FXR-modulating compounds having a structure of formula (I), including pharmaceutically acceptable salts, esters, and stereoisomers. The patent contains 19 claims and covers therapeutic applications including liver disease (A61P 1/16), metabolic disorders, cardiovascular conditions, and kidney disease.

Boehringer Ingelheim Patent for sGC Activators in Systemic Sclerosis Treatment

The USPTO granted patent US12600715B2 to Boehringer Ingelheim International GmbH covering methods for treating systemic sclerosis using soluble guanylate cyclase (sGC) activators of formula (I) or their pharmaceutically acceptable salts. The patent names Mary Ruth Flack, Julia Kaufman, and Indra Sethy-Coraci as inventors and includes 20 claims spanning therapeutic applications including respiratory, dermatological, pain, and immunological indications. This method patent provides Boehringer Ingelheim with enforceable exclusivity over the specified sGC activator treatment protocol for systemic sclerosis in the United States.

Hutchmed Crystalline Forms Patent Grant US12600713B2

USPTO granted patent US12600713B2 to Hutchmed Limited on April 14, 2026 for crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide, a pharmaceutical compound. Inventors are Zhenping Wu, Wenji Li, and Yuping Chu. The patent contains 28 claims and was filed on February 27, 2024.

Hoffmann-La Roche Granted Amino-Pyrimidine Amide Patent US12600712B2

USPTO granted Patent US12600712B2 to Hoffmann-La Roche Inc. on April 14, 2026, covering amino-pyrimidine amide compounds with general formula (I) and methods of using such compounds. The patent includes 11 claims and CPC classifications C07D 403/06 and C07D 491/107 in organic chemistry. The filing date was December 7, 2022, with Application No. 18062644.

Nonpeptide Somatostatin Type 5 Receptor Agonists and Uses Thereof

USPTO granted patent US12600709B2 to Crinetics Pharmaceuticals covering nonpeptide somatostatin type 5 receptor agonists, methods of making the compounds, pharmaceutical compositions, and methods of using the compounds in treating conditions that benefit from somatostatin modulation. The patent includes 4 claims.

MDMA Prodrug Carbamate Compounds - Apoapsis Holdings

USPTO granted Patent US12600708B2 to Apoapsis Holdings, LLC for novel MDMA prodrug carbamate compounds and synthesis methods. The patent covers 19 claims for compounds that are enzymatically cleaved in vivo to produce low-toxicity alcohols. The inventors include Denton W. Hoyer, Robert F. Roscow, Rong Ling, and Chuanjun Gao.

Cannabinoid Derivatives, Precursors and Uses - Patent US12600707B2

USPTO granted patent US12600707B2 to Kare Chemical Technologies Inc. on April 14, 2026, covering new cannabinoid derivatives, precursors, and processes for their preparation. The patent also claims pharmaceutical and analytical uses of these compounds. The patent (10 claims) protects the invention until 2040 based on the September 2020 filing date.

University of Pittsburgh Heat Shock Protein Modulator Patent for Huntington Disease

USPTO granted patent US12600705B2 to University of Pittsburgh for thiadiazine compounds as heat shock protein modulators. The patent covers therapeutic applications for Huntington disease, other neurodegenerative disorders, and cancer. The patent includes 13 claims.

US12600703B2 - Farnesyl Dibenzodiazepinone Synthesis Patent

USPTO granted patent US12600703B2 to AMO Pharma Ltd. covering methods of synthesizing farnesyl dibenzodiazepinone compounds, including AMO-01. The patent has 4 claims and was filed on May 28, 2021. Patent grants establish legally enforceable intellectual property rights for the disclosed chemical synthesis methods.

Roche Diagnostics Imidazolium Reagent Mass Spectrometry Patent Grant

The USPTO granted Patent US12600700B2 to Roche Diagnostics Operations, Inc. covering imidazolium compounds and methods for mass spectrometric determination of analyte molecules. The patent, applied for in November 2022 under application number 17991282, was granted with 14 claims. The invention relates to compounds suitable for use in mass spectrometry and associated analytical methods.

Kinase Inhibitors Patent - VIDYA Therapeutics, Inc.

USPTO granted Patent US12600698B2 to VIDYA Therapeutics, Inc. on April 14, 2026. The patent covers Bruton tyrosine kinase (BTK) inhibitors designed to penetrate the central nervous system, including pharmaceutical compositions and methods of treatment. The patent includes 21 claims with an August 2022 filing date.

Thiosemicarbazates and Uses Thereof - US12600699B2

The USPTO granted Patent US12600699B2 to The Feinstein Institutes for Medical Research covering thiosemicarbazates, thiocarbamates, thiocarbazates, semithiocarbazates, peptides, aza-amino acid conjugates, and azapeptides. The patent also protects a chemoselective functionalization protocol using Mitsunobu reaction for site-specific alkylation. Methods for preparing and using these compounds in drug discovery, diagnosis, inhibition, prevention and treatment of diseases are included in the 17 granted claims.

Markers, Conjugates, Compositions and Methods for Hypoxia Imaging, Mapping, and Therapy

USPTO granted patent US12600742B2 to WWIKY Biosciences Inc. on April 14, 2026. The patent covers markers, conjugates, compositions and methods for hypoxia imaging, mapping, and therapy using bio-reductively activated compounds with click chemistry. Inventors include Piyush Kumar, Hassan Elsaidi, Leonard Irving Wiebe, and Michael Weinfeld. The patent includes 5 claims.

Compositions and Methods for Removal of NMP Degradation Products from NMP Purification Systems

USPTO granted patent US12600697B2 to Refined Technologies, Inc. covering methods for cleaning N-methyl-2-pyrrolidone (NMP) purification and recovery systems. The patent claims compositions and methods using a cleaning solution containing a solvent with a primary amine and hydroxyl group, injected into reflux drums and reboilers, circulated through separation towers to solubilize foulants, then drained. The patent was filed May 25, 2022, and contains 15 claims under CPC classifications C07D 207/267 and C07D 201/16.

N-Acylhydrazonic Compounds Treat Amyloid Diseases, Patent Grant

USPTO granted patent US12600701B2 to Faculdades Católicas for N-acylhydrazonic compounds structurally derived from 1-methyl-1H-imidazole-2-carboxaldehyde for preventing and treating amyloid degenerative aggregopathies including Alzheimer's disease, Parkinson's disease, and type 2 diabetes, as well as non-amyloid conditions such as cataracts. The patent covers four specific compounds and pharmaceutical compositions containing them.

Crystalline Forms of Quinazolinyl-Benzonitrile Compound and Ocular Formulations

USPTO granted patent US12600702B2 to Bausch + Lomb Ireland Limited for crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile and formulations thereof. The patent covers methods for treating ocular surface pain, dry eye disease, and ocular hyperemia. The application was filed on February 13, 2020 under application number 17430819, with 16 claims granted.

Japan Science and Technology Agency V-ATPase Inhibitor Patent

USPTO granted patent US12599588B2 to Japan Science and Technology Agency for an inhibitor of Na+-translocating V-ATPase activity. The compound serves as an antibacterial agent and medicine with applications in antibacterial and screening methods. The patent application was filed January 15, 2020, contains 12 claims, and covers compounds with specific structural features including hydroxy, alkoxy, and amino substituents on phenyl groups.

Bayer Aktiengesellschaft Substituted Isophthalic Acid Diamides Herbicide Patent, US12599136B2

The USPTO granted Patent US12599136B2 to Bayer Aktiengesellschaft covering substituted isophthalic acid diamides of general formula (I) for use as herbicides. The patent includes 15 claims covering compounds where X and Y are hydrogen, alkyl, or halogen radicals, and Z1 and Z2 are alkyl, cycloalkyl, or phenyl radicals with a heterocyclic Q ring. The patent was filed April 1, 2021, under Application No. 17995662.

Pyrrole Compounds Patent - Aligos Therapeutics - US12599582B2

USPTO granted Patent US12599582B2 to Aligos Therapeutics covering pyrrole compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions, and methods of treating diseases and conditions. The patent names inventors Sandrine Vendeville, David Bernard Smith, Leonid Beigelman, and Vladimir Serebryany. The application was filed August 22, 2023, with 2 claims granted.

Chlorinated Tetralin Compounds and Pharmaceutical Compositions

USPTO granted patent US12599587B2 to Springworks Therapeutics, Inc. on April 14, 2026. The patent covers chlorinated tetralin compounds and pharmaceutical compositions, classified under C07D 233/88 and A61K 31/417. The application (No. 18490993) was filed on October 20, 2023, and the granted patent contains 19 claims.

Inhibitors of SARM1 for Axonal Degeneration Treatment

USPTO granted patent US12595252B2 to DISARM Therapeutics, Inc. on April 7, 2026, covering SARM1 inhibitor compounds and methods for treating axonal degeneration. The patent includes 4 claims and covers specific chemical compositions useful in neurological disease treatment.

MET Kinase Inhibitor Patent US12595245B2 Granted

The USPTO granted patent US12595245B2 to Celyn Therapeutics, Inc. covering MET receptor tyrosine kinase inhibitor compounds, pharmaceutical compositions, and methods of use for treating disease. The patent contains 18 claims and is classified under CPC codes C07D 401/12, C07D 215/22, C07D 405/14, and C07D 471/04. This grant establishes enforceable intellectual property rights for the disclosed MET kinase inhibitors.

PRMT5 inhibitors for cancer treatment

USPTO granted patent US12595248B2 to Merck Sharp & Dohme LLC covering PRMT5 inhibitor compounds of Formula I and their use in treating cancer, sickle cell disease, and hereditary persistence of foetal hemoglobin (HPFH). The patent includes 32 claims covering the compound compositions, methods of making, pharmaceutical formulations, and treatment methods.

Substituted pyrazolo piperidine carboxylic acids

USPTO granted patent US12595247B2 to Bayer Aktiengesellschaft covering substituted pyrazolo piperidine carboxylic acids, their salts, and processes for preparation. The patent includes 6 claims and lists 18 inventors. The compounds are directed toward cardiovascular and cardiac diseases, including heart failure with reduced, mid-range, and preserved ejection fraction.

PRMT5 inhibitors for cancer, sickle cell, and HPFH treatment

USPTO granted patent US12595262B2 to Merck Sharp & Dohme LLC for PRMT5 inhibitor compounds and methods of treatment for cancer, sickle cell disease, and hereditary persistence of foetal hemoglobin (HPFH). The patent covers 14 claims including compounds A through D and their pharmaceutical salts, esters, and prodrugs.

Heterocyclic GLP-1 agonists

USPTO granted patent US12595264B2 to Gasherbrum Bio, Inc. on April 7, 2026, covering heterocyclic GLP-1 receptor agonists of Formula (I), including pharmaceutical salts, solvates, and compositions. The patent names six inventors and contains 24 claims, with CPC classifications spanning heterocyclic chemistry (C07D 487/04), phosphorus compounds (C07F 9/6561), and pharmaceutical formulations (A61K 31/4985, A61K 38/26).

P2X3 receptor antagonist patent, Beijing Tide Pharma, 6 claims

P2X3 receptor antagonist patent, Beijing Tide Pharma, 6 claims

Benzo nitrogen-containing heteroaromatic ring derivative for complement factor B treatment

The USPTO granted patent US12595270B2 to Xizang Haisco Pharmaceutical Co., Ltd. covering a benzo nitrogen-containing heteroaromatic ring derivative (general formula I) and its use in treating diseases associated with complement factor B activity or expression. The patent includes 8 claims encompassing the compound, stereoisomers, deuterates, solvates, prodrugs, metabolites, and pharmaceutically acceptable salts or co-crystals.

Acid anhydride compound, polyamideimide resin and film

USPTO granted Patent US12595268B2 to Korea Advanced Institute of Science and Technology (KAIST) for a novel acid anhydride compound and polyamideimide resin and film utilizing the same. The invention provides high thermal resistance, low coefficient of thermal expansion, and colorless transparency properties. The patent contains 11 claims and was filed under Application No. 18517326.

Syngenta patent 12595266B2, pesticide sulfur compounds, Apr 07

Syngenta patent 12595266B2, pesticide sulfur compounds, Apr 07

Amide EZH2 Inhibitor Patent - Preparation Method and Medical Applications

The USPTO granted patent US12595267B2 to Shanghai Synergy Pharmaceutical Sciences Co., Ltd. covering an amide small molecule compound that inhibits EZH2 (Zeste gene enhancer homolog 2). The patent protects methods for preparing the compound and its use in treating EZH2-mediated diseases including tumors, myeloproliferative diseases, and autoimmune diseases. The patent contains 11 claims and names 19 inventors.

MDM2 Inhibitor Patent Granted to Bahcesehir University

The USPTO granted Bahcesehir University Patent No. US12595232B2 for a novel Mouse Double Minute 2 (MDM2) inhibitor compound. The patent covers formula (I) compounds or pharmaceutically acceptable derivatives for inhibiting MDM2 activity. Application No. 17904403 was filed February 16, 2021, and the patent contains 2 claims.

Bioactive benzocycloheptene analogues as PI3K/MK2 inhibitors

USPTO granted Patent US12595234B2 to the Council of Scientific & Industrial Research for bioactive benzocycloheptene analogues that inhibit PI3K and MK2. The patent covers compounds for treating type 2 diabetes, inflammatory conditions, epilepsy, cancer, and CNS disorders. The patent contains 10 claims.

STAT3 inhibitor prodrug patent compositions

USPTO granted patent US12594265B2 to Ohio State Innovation Foundation for prodrug compositions inhibiting STAT3 (including STAT3). The patent covers pharmaceutical compositions for treating inflammatory disorders (including multiple sclerosis) and cancers of uncontrolled cellular proliferation. Inventors: Yuhong Yang, Chenglong Li, Michael Racke. Application No. 17821286, 19 claims.

2,6-dioxo-3,6-dihydropyrimidine compound, bactericide, nematicide, and antifungal agent

USPTO granted patent US12593845B2 to Nippon Soda Co., Ltd. on April 7, 2026, covering a 2,6-dioxo-3,6-dihydropyrimidine compound for use as an agricultural and horticultural bactericide, nematicide, and medical/veterinary antifungal agent. The patent contains 4 claims and names 9 inventors including Takaaki Teranishi and Hajime Shimomura.

Thiosemicarbazates and Uses Thereof

The USPTO granted patent US12595233B2 to The Feinstein Institutes for Medical Research on April 7, 2026. The patent covers thiosemicarbazates, thiocarbazates, semithiocarbazates, peptides, aza-amino acid conjugates, and azapeptides, along with methods for their synthesis and applications in drug discovery, diagnosis, inhibition, prevention, and treatment of diseases. The patent names Yousef Al-Abed and Ahmad Altiti as inventors.

Mesembrine Crystalline Salt Patent Grant

USPTO granted Patent US12595231B2 to Kanna Health Ltd covering novel crystalline salt forms of mesembrine, specifically mesembrine besylate salt. The patent, filed under Application No. 18614136 with 18 claims, covers the chemical compound (C17H23NO3) and its use as a medicament.

Spiromacrocyclic orexin 2 receptor agonists

USPTO granted Patent No. US12590106B2 to H. Lundbeck A/S for novel spiromacrocyclic orexin 2 receptor agonists used in CNS treatments. The patent, covering 18 claims, names 11 inventors including Karsten Juhl, Wanwan Yu, and Thomas Leegaard Andersen, with application originally filed as EP19195185.